Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Fennec Pharmaceuticals (FENC) and InfuSystem Holdings (INFU)

Tipranks - Tipranks - Sat Feb 21, 9:56AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch Health Companies (BHC – Research Report), Fennec Pharmaceuticals (FENC – Research Report) and InfuSystem Holdings (INFU – Research Report).

President's Day Sale - 70% Off

Bausch Health Companies (BHC)

In a report released today, Michael Nedelcovych from TD Cowen maintained a Hold rating on Bausch Health Companies, with a price target of $7.00. The company’s shares closed last Friday at $6.08.

According to TipRanks.com, Nedelcovych is a 2-star analyst with an average return of 0.8% and a 50.0% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Royalty Pharma, and Novo Nordisk. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $7.50 average price target, which is a 26.1% upside from current levels. In a report released yesterday, Truist Financial also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

Fennec Pharmaceuticals (FENC)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Fennec Pharmaceuticals today. The company’s shares closed last Friday at $8.66.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 34.1% and a 59.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Xtant Medical Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fennec Pharmaceuticals with a $15.67 average price target, implying a 79.3% upside from current levels. In a report issued on February 12, B. Riley Securities also initiated coverage with a Buy rating on the stock with a $16.00 price target.

InfuSystem Holdings (INFU)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on InfuSystem Holdings. The company’s shares closed last Friday at $8.05.

According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.8% and a 36.3% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Dyadic International. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for InfuSystem Holdings.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).